UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 23, 2014
CANNAPHARMARX, INC.
---------------------
(Exact name of Registrant as specified in its charter)
Delaware 000-27055 24-4635140
---------------------------- ------------------------ --------------------
(State or other jurisdiction (Commission File Number) (IRS Employer Identi
of incorporation) -fication No.)
One Collins Drive, Salem Business Center, Carneys Point, NJ 08069-3640
--------------------------------------------------
(Address of principal executive offices)
720-939-1133
-----------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
GOLDEN DRAGON HOLDING CO.
---------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officer
On October 23, 2014, a majority of the Board of Directors voted to
terminate Gary Cohen as President of the Company. Mr. Cohen's termination as
President was effective on October 23, 2014. Mr. Cohen remains a director of the
Company.
On October 23, 2014, a majority of the Board of Directors appointed Mathew
Sherwood a director of the Company. Mr. Sherwood's appointment as a director was
effective October 23, 2014. Mr. Sherwood is our Vice President of Product
Development.
Mathew Sherwood, age 37
Vice President, Product Development and Director
Mr. Sherwood has more than 20 years of experience in healthcare, both in
private practice and as a consultant. Mr. Sherwood worked as a board-certified
optician as well as a consultant in both practice management and optical
laboratory solutions. As an optician, Mr. Sherwood developed solutions for
ophthalmic lens manufacturing and high-performance prescription applications.
For most of the last decade, Mr. Sherwood has turned his focus to medical
cannabinoid solutions, developing a variety of cannabinoid-based solutions, and
has a deep understanding of the potential of cannabinoid products. Mr. Sherwood
specializes in extraction technologies and the design and manufacturing of novel
delivery systems. Mr. Sherwood is a co-founder of the National Association of
Cannabinoid Pharmaceuticals and continues to serve as an industry liaison.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CANNAPHARMRARX, INC.
Formerly Golden Dragon Holding Co.
By: /s/ Gerry Crocker
-----------------------------------
Chief Executive Officer
Date: October 24, 2014
- 3
